Trial Profile
The RITAI Cohort. An Observational Study on Serious Adverse Events Occuring After Rituximab Off-label Use for Auto-immune Disorders [Etude observationnelle des evenements indesirables graves survenant chez les patients traites par rituximab pour maladie dysimmunitaire hors polyarthrite rhumatoide]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms Cohorte RITAI; RITAI
- 23 Aug 2011 New trial record